No Data
No Data
Medibio Begins Phase Two Trial for Sleep Algorithm
Medibio (ASX:MEB) began a phase two trial investigating the accuracy and performance of its algorithm to detect major depressive episodes via an analysis of sleep signals. The trial, which aims to rec
Medibio Completes Phase One Depressive Episode Sleep Trial
Medibio (ASX:MEB) completed its phase one study for the use of an artificial intelligence algorithm to diagnose the potential presence of depressive episodes in patients undergoing polysomnography ass
US FDA Denies Breakthrough Device Designation for Medibio's Depression Diagnostic Device
Medibio (ASX:MEB) said on Friday that the US Food and Drug Administration decided that the current version of its depression diagnostic device MEB-001 does not meet the criteria as a breakthrough devi
No Data